Ranbaxy restarts generic Lipitor production; More Avandia suits filed; Genentech tax adjustment put hurt on Oregon town;

@FiercePharma: Sanofi's new 6-in-1 vaccine won backing from Europe's CHMP. Would compete with $GSK's Infanrix Hexa. News | Follow @FiercePharma

@EricPFierce: Elan CEO Martin gives shareholders a taste of honey. More | Follow @EricPFierce

@AlisonBFierce: The flu vaccine was effective in only 56% of those who received it, largely failing to protect against the elderly. More | Follow @AlisonBFierce

> Ranbaxy is resuming production of generic Lipitor, which it halted after the recall of some lots because they might have been tainted by ground glass. Story

> Kentucky has filed suit against GlaxoSmithKline ($GSK), accusing it of some of the same kinds of indiscretions with Avandia which figured into its $3 billion settlement last year with the feds. News

> Florida has joined the states looking at legislating limits on biosimilars. More

> Some insurers are raising questions about the $235,000 cost of Juxtapid, a treatment for people with extremely high cholesterol who currently have to have their blood filtered. Story

> Roche ($RHHBY) subsidiary Genentech expects to fill nearly 600 new positions this year, many at their South San Francisco headquarters. Item

Medical Device News

 @FierceMedDev: Abbott chops 200 jobs at Ireland plant. Story | Follow @FierceMedDev

 @MarkHFierce: A cancer diagnostic test you could use yourself in the bathroom at home? It's coming... More | Follow @MarkHFierce

 @DamianFierce: Despite a revenue jump, Volcano's profits tanked in Q4. News | Follow @DamianFierce

> J&J's DePuy recalls knee component over risk of limb loss. Story

> Stryker sued over metal-hip safety shortfalls. Item

> Abiomed gets out from under FDA's Impella warning letter. Report

Biotech News

 @FierceBiotech: FDA approved T-DM1 for patients with HER2-positive breast cancer. Story | Follow @FierceBiotech

@JohnCFierce: Elan lines up biotech deals as it preps for $3B Tysabri windfall. Report | Follow @JohnCFierce

> India probes cause of 436 clinical trial deaths. Item

> J&J stakes out Boston/Cambridge HQ for new innovation center. Report

> Report: Booming Genentech plans 600 new hires in 2013. News

> Upstart Blaze banks $8.5M A round for new cancer surgery tech. Article

And finally... The $162.6 million reduction in the assessed valuation of a Genentech facility in Hillsboro, OR, has put a world of hurt on that town's municipal budget. Story

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.